Reporting this week in JEM, the Winau lab identified a new pathway involving scramblase TMEM16F that preserves efficient T cell responses to control viral infection. These findings provide a novel target for therapy against chronic diseases, such as cancer, HIV and hep B virus infections.
A group led by Frederick Alt, developed a technology to greatly speed up HIV development in mice. The group’s method generates mouse models with built-in human immune systems. The model rapidly recapitulates what the human immune system does, enabling researchers to continuously test and tweak potential HIV vaccines.
The Winau Lab has discovered a new mechanism for skin inflammation. This work, recently published in Nature Immunology, forms the basis for future therapeutic strategies against inflammatory skin diseases, such as poison ivy dermatitis and psoriasis.
Reporting this week in Nature, scientists in Boston Children’s Hospital’s Program in Cellular and Molecular Medicine (PCMM) describe new potential avenues for controlling both sepsis and the runaway bacterial infections that provoke it.
Now, a research team led by Wesley Wong has made a major advance by developing an inexpensive method that permits analysis of the force responses of thousands of similar molecules simultaneously.
Study reveals new avenue for thinking about brain development, brain tumors and neurodevelopmental/psychiatric diseases
Over the last couple of years Judy Lieberman’s lab has uncovered evidence for what could be an evolutionarily ancient form of immune defense directed against intracellular pathogens. In a 2014 Cell paper, her lab revealed that the immune system’s T-cells can kill intracellular bacteria directly by pummeling infected cells with three proteins: perforin, granulysin and granzymes
In a recent Cell paper, a team led by Hao Wu, PhD, used electronic microscopy to reveal how RAG1 and 2 interact at a structural level, both with each other and with DNA.
Researchers in Dr. Fred Alt's laboratory used a novel in vivo mouse model system to resolve longstanding questions regarding the influence of DNA sequences on AID targeting and mutational outcomes during antibody diversification.
In a new paper in Cell Stem Cell, Dr. Yi Zhang's team report that they’ve extended their work to improve the efficiency of SCNT in human cells.
An AIDS vaccine able to fight any HIV strain has thus far eluded science. HIV frequently mutates its coat protein, dodging vaccine makers’ efforts to elicit sufficiently broadly neutralizing antibodies.
Yet sometimes HIV-infected people can produce such antibodies on their own. This usually requires years of exposure to the virus, allowing the immune system to modify its antibodies over time to keep up with HIV mutations. But the goal is generally achieved too late in the game to prevent them from being infected.
“Only a small fraction of patients are able to develop broadly neutralizing antibodies, and by the time they do, the virus has already integrated into the genomes of their T-cells,” says Ming Tian, PhD, of Boston Children’s Hospital’s Program… Read More »
Dr. Xing Liu (left), a postdoctoral fellow in the Lieberman lab, will investigate the underlying mechanism responsible for global mRNA decay during programmed cell death. Decay of mRNA,… Read More »
The Medal for Young Scientist is awarded annually by the Indian National Science Academy to young scientists of extraordinary promise and creativity who made notable research contributions in Science… Read More »